Preparation and acute toxicology of nano-magnetic ferrofluid

Abstract

The nano-magnetic ferrofluid was prepared by chemical coprecipitation and its acute toxicology was investigated. The effective diameter (Eff. Diam.) of the magnetic particles was about 19.9 nm, and the concentration of the ferrofluid was 17.54 mg/ml. The acute toxic reaction and the main viscera pathological morphology of mice were evaluated after oral, intravenous and intraperitoneal administration of the nano-magnetic ferrofluid of different doses respectively. Half lethal dose (LD₅₀)>2104.8 mg/kg, maximum non-effect dose (ED₀)=320.10mg/kg with oral; LD₅₀>438.50 mg/kg, ED₀=160.05 mg/kg with intravenous route; and LD₅₀>1578.6 mg/kg, ED₀=320.10 mg/kg with intraperitoneal administration. Degeneration and necrosis of viscera were not found. So the nano-magnetic ferrofluid, of which toxicity is very low, may be used as a drug carrier.

Keywords

nano-magnetic ferrofluid / preparation / acute toxicity / drug carrier

References

[1] RajK, MoskowitzR. Commerical applications of ferrofluids. J Magn Magn Mater, 1990, 85233-233

[2] HisaeI, KotaO, MikiA, et al. . Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int J Cancer, 2000, 89(4): 337-337

[3] FrijaG, ClementO, de KervilerE. Overview of contrast enhancement with iron oxides. Invest Radiol, 1994, 29(Suppl 2): 75-75

[4] GoodwinS C, BittnerC A, PetersonC L, et al. . Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol Sci, 2001, 60(1): 177-177

[5] JordanA, ScholzR, WustP, et al. . Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia, 1997, 13(6): 587-587

[6] LubbeA S, BergemannC, RiessH, et al. . Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res, 1996, 56(20): 4686-4686

[7] PanyamJ, LabhasetwarV. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev, 2003, 55(3): 329-329

[8] Yudelson, Joseph S. Preparation and magnetic properties of very small magnetite-dextran particles. United States Patent, 5349957

[9] SFDA. Good Laboratory Practice 2003 (Chinese). Chinese State Food and Drug Administration. 2003. 8

[10] Guidance for industry: single dose acute toxicity testing for pharmaceutical. CEDR, 1996.

[11] Toxicokinetics: the assessment of systemic exposure in toxicity studies. CEDR, 1995.

[12] HafeliU O, PauerG J. In vitro and in vivo toxicity of magnetic microspheres. J Magn Magn Mater, 1999, 9476-76

[13] WagnerS, SchnorrJ, PilgrimmH, et al. . Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol, 2002, 37(4): 167-167

[14] LawaczeckR, BauerH, FrenzelT, et al. . Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Acta Radiol, 1997, 38(4 Pt 1): 584-584

[15] LacavaZ G M, AzevedoR B, MartinsE V, et al. . Biological effects of magnetic fluids: toxicity studies. J Magn Magn Mater, 1999, 201431-431